0000000000459601

AUTHOR

R. G. Simonetti

showing 9 related works from this author

Antibody Pattern of HCV Infection and Hepatocellular Carcinoma in Italy: A Case Control Study

1994

The association of hepatitis C virus (HCV) infection with hepatocellular carcinoma (HCC) and the presence of a specific antibody pattern was assessed by means of a case-control study conducted in Italy on 65 consecutive newly diagnosed HCC cases and 99 sex- and age-matched control patients with chronic nonhepatic disease. The prevalences of antibody to HCV (anti-HCV) and hepatitis B surface antigen (HBsAg) observed were 66.2% and 24.6%, respectively. The relative risk for the association of each of the two markers with HCC, as calculated by multiple logistic analysis, was 26.9 (95% confidence intervals (CI): 9.9–72.5) for anti-HCV and 11.4 (95% CI: 3.1–41.1) for HBsAg. Thus, they constitute…

medicine.medical_specialtyHBsAgbiologybusiness.industryHepatitis C virusCase-control studyDiseasemedicine.disease_causemedicine.diseaseGastroenterologyVirologydigestive system diseasesConfidence intervalInternal medicineHepatocellular carcinomaRelative riskmedicinebiology.proteinAntibodybusiness
researchProduct

Characteristics of hepatocellular carcinoma in Italy.

1998

This study aimed to assess the main features of hepatocellular carcinoma at the time of diagnosis in Italy, particularly in relation to the presence or absence of underlying cirrhosis, hepatitis virus marker patterns, age of the subjects and alpha-foetoprotein values.A total of 1148 patients with hepatocellular carcinoma seen at 14 Italian hospitals in the 1-year period from May 1996 to May 1997 were the subjects of this prevalence study. Both newly diagnosed cases (incident cases) and cases diagnosed before May 1996 but still attending the hospitals during the study period (prevalent cases) were included.We found that 71.1% of cases were positive for hepatitis C virus antibodies but negati…

AdultLiver CirrhosisMalemedicine.medical_specialtyHBsAgCarcinoma HepatocellularHepatitis C virusmedicine.disease_causeGastroenterologyAge DistributionInternal medicineHepatitis VirusesmedicinePrevalenceHumansSex DistributionAgedHepatitisAged 80 and overHepatitis B Surface AntigensHepatologybusiness.industryIncidence (epidemiology)Liver NeoplasmsLiver cancer; risk factors; ItalyHepatitis BHepatitis C AntibodiesMiddle Agedmedicine.diseaseLogistic ModelsItalyHepatocellular carcinomaImmunologyRegression AnalysisFemalealpha-FetoproteinsLiver cancerbusinessViral hepatitisJournal of hepatology
researchProduct

An Unusual Presentation of Zollinger-Ellison Syndrome

2013

Abstract Zollinger-Ellison syndrome is an often progressive, persistent and frequently life-threatening disease, described for the first time as characterized by ulceration of the upper jejunum, hypersecretion of gastric acid and non-beta islet cell tumors of the pancreas; this syndrome is due to the hypersecretion of gastrin. We report a case of Zollinger-Ellison syndrome presenting as severe esophagitis evolving in stenosis, which demonstrates how a delayed diagnosis may induce risk of disease spreading. In this setting new diagnostic approaches, such as somatostatin receptor scanning and positron emission tomography with 68 Ga-labeled octreotide, could be particularly useful, as well as …

Positron emission tomographyPathologymedicine.medical_specialtySettore MED/09 - Medicina InternaOctreotideZollinger-Ellison syndromePublished online: January 2013medicinelcsh:RC799-869GastrinSomatostatin receptorbusiness.industryGastroenterologyZollinger ellison. severe esophagitismedicine.diseaseZollinger-Ellison syndromemedicine.anatomical_structureOctreoscanRadionuclide therapyGastric acidlcsh:Diseases of the digestive system. GastroenterologyEsophageal stricturesPancreasbusinessEsophagitismedicine.drugCase Reports in Gastroenterology
researchProduct

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model.

2000

OBJECTIVE: Percutaneous ethanol injection may prolong the survival of patients with small hepatocellular carcinoma associated with cirrhosis. The aim was to identify prognostic factors of survival and of local recurrence, as well as separate new lesions. METHODS: We performed Cox regression analysis in 115 consecutive patients with hepatocellular carcinoma (81 Child-Pugh class A, 34 Child-Pugh class B) treated by percutaneous ethanol injection. The validity of the model was tested by comparing predicted and observed survival in 105 independent patients from an external series. RESULTS: Overall survival rates were 89%, 63%, and 43% at 1, 2, and 3 yr, respectively. The 1-, 2-, and 3-yr surviv…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentInjections IntralesionalSmall-cell carcinomaGastroenterologyLiver Function TestsInternal medicinemedicineCarcinomaHumansSurvival rateSerum AlbuminAgedHepatologymedicine.diagnostic_testEthanolbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseasedigestive system diseasesSurgerySurvival RateHepatocellular carcinomaFemalePercutaneous ethanol injectionbusinessLiver function testsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Hepatitis C Viremia in Chronic Liver Disease: Relationship to Interferon-α or Corticosteroid Treatment

1994

We assessed the pattern of hepatitis C viremia in chronic liver disease by studying 100 hepatitis C virus antibody–positive patients: 48 with chronic hepatitis, 21 with cirrhosis and 31 with hepatocellular carcinoma and cirrhosis. Serum hepatitis C virus RNA was detected by means of both the conventional nested polymerase chain reaction and a newly developed assay based on branched DNA that can also quantify viremia. Hepatitis C virus RNA was found in 94 of 100 patients with polymerase chain reaction and in 71 of 100 patients with branched-DNA (p < 0.001). Mean viremia level (× 103 genome equivalents/ml ± S.D.), as assessed with the branched-DNA test, was 5,700 ± 7,618 in the 48 patients wi…

Hepatitismedicine.medical_specialtyCirrhosisHepatologybusiness.industryHepatitis C virusHepatitis CHepatologymedicine.diseasemedicine.disease_causeChronic liver diseaseLiver diseaseInternal medicineHepatocellular carcinomaImmunologymedicinebusiness
researchProduct

Spontaneous Bacterial Peritonitis: A Prospective Investigation in Predominantly Nonalcoholic Cirrhotic Patients

1983

Two hundred and twenty-four consecutive inpatients with cirrhosis, mostly of nonalcoholic etiology, and ascites were prospectively investigated on admission for spontaneous bacterial peritonitis (SBP) by culture, smear, and polymorphonuclear (PMN) counts of ascitic fluid. Positive cultures were found in 54 patients. A possible intraabdominal source of infection was apparent in five of them, all with clinically overt peritonitis (secondary peritonitis). No intraabdominal source of infection was identified in the remaining 49. These patients were classified into the following groups: (a) SBP, 27 patients (positive cultures plus PMN counts ± 250 per mm3). Nine of them had no clinical features …

Liver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.drug_classAntibioticsPeritonitisPeritonitisGastroenterologySpontaneous bacterial peritonitisInternal medicineAscitesHumansMedicineProspective StudiesProspective cohort studyAgedHepatologybusiness.industryAscitesBacterial InfectionsMiddle Agedmedicine.diseaseSurgeryEtiologyPositive cultureFemalemedicine.symptombusinessHepatology
researchProduct

Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group.

1997

Ethanol injection has been reported to be effective in the treatment of hepatocellular carcinoma, but no controlled randomized trials have been performed. We therefore performed a trial comparing ethanol injection with an untreated, matched historical comparison group in the treatment of hepatocellular carcinoma.From 1992 to 1993, 35 patients (14 Child's A and 21 Child's B cirrhosis) with small (4 cm) hepatocellular carcinoma associated with cirrhosis were treated by ethanol injection. Each patient was matched with an untreated case (followed up during the period 1984-89) for variables known to have independent prognostic value (age, Child's classification, number of lesions, alpha-fetoprot…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentEthanol InjectionGastroenterologylaw.inventionRandomized controlled triallawInternal medicinemedicineHumansChemotherapyEthanolbusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseConfidence intervalSurvival RateHepatocellular carcinomaCase-Control StudiesSolventsFemalePercutaneous ethanol injectionComplicationbusinessScandinavian journal of gastroenterology
researchProduct

Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma.

1989

MaleCarcinoma HepatocellularbiologyEpitheliomaHepatitis Viral Humanbusiness.industryHepatitis C virusLiver NeoplasmsGeneral Medicinemedicine.diseasemedicine.disease_causeAntibodies ViralVirologyHepatitis CHepatocellular carcinomaImmunologyHepatitis VirusesCarcinomamedicinebiology.proteinPrevalenceHumansFemaleAntibodybusinessLancet (London, England)
researchProduct

Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.

1992

Objective To determine whether chronic hepatitis C virus (HCV) infection is an independent risk factor for hepatocellular carcinoma and whether it increases the cirrhosis-related risk for hepatocellular carcinoma. Design Two pair-matched case-control studies. Setting A referral-based hospital. Patients In study I, 212 patients with hepatocellular carcinoma (197 of whom had known underlying cirrhosis) were compared with controls who had chronic nonhepatic diseases. In study II, the 197 patients with hepatocellular carcinoma and cirrhosis were compared with 197 pair-matched controls who had cirrhosis but not hepatocellular carcinoma. Measurements Levels of antibody to HCV (anti-HCV), hepatiti…

Liver CirrhosisMalemedicine.medical_specialtyHBsAgCirrhosisCarcinoma HepatocellularHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyRisk FactorsInternal medicineInternal MedicinemedicineCarcinomaPrevalenceHumansHepatitis AntibodiesRisk factorHepatitis B AntibodiesSicilyAgedHepatitis B Surface Antigensbusiness.industryLiver NeoplasmsCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseHepatitis B Core AntigensHepatitis Cdigestive system diseasesHepatocellular carcinomaCase-Control StudiesFemalebusinessAnnals of internal medicine
researchProduct